Financial Data and Key Metrics Changes - Funds from operations (FFO) per share for Q3 2025 was $2.27, representing a 6.6% increase compared to the same quarter last year [6][10] - Quarter-end leasing was at 96.7%, with occupancy at 95.9%, and average quarterly occupancy was 95.7%, down 100 basis points from Q3 2023 [6][10] - Cash same-store NOI rose 6.9% for the quarter and 6.2% year-to-date [7] Business Line Data and Key Metrics Changes - Quarterly releasing spreads were 36% GAAP and 22% cash for leases signed during the quarter, with year-to-date results at 42% and 27% GAAP and cash, respectively [6][10] - The company reported a quarterly retention rate of almost 80%, indicating a cautious nature among tenants [8] Market Data and Key Metrics Changes - The market remains somewhat bifurcated, with improved activity in smaller spaces (50,000 square feet and below) but larger spaces experiencing delays in decision-making [7][8] - The company is reforecasting 2025 starts to $200 million based on current demand levels, with a noted decline in the supply pipeline [9] Company Strategy and Development Direction - The company aims to capitalize on development opportunities earlier than private peers, leveraging its balance sheet strength and existing tenant expansion needs [9] - The focus is on geographic and tenant diversity to stabilize earnings regardless of economic conditions [7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improved market activity and the potential for a stronger leasing environment in the future [15] - The company is seeing signs of macro uncertainty subsiding, which could strengthen consumer and corporate confidence [13] Other Important Information - The company has a flexible balance sheet with a debt-to-total market capitalization of 14.1% and an unadjusted debt-to-EBITDA ratio of 2.9 times [11] - Tenant collections remain healthy, with uncollectible rents estimated to be in the 35 to 40 basis point range as a percentage of revenues [13] Q&A Session Summary Question: Expansion on leasing and development pipeline - Management noted that conversations regarding leasing have improved since May, with a high retention rate indicating tenant stability [18][19] Question: Construction costs and market rents - Construction pricing has decreased by 10% to 12%, and current construction pricing is still yielding acceptable returns [25][26] Question: Development pipeline availability and leasing activity - Management indicated that while there is activity in the development pipeline, the pace of leasing has been slower than desired [31][32] Question: Average rent per square foot and GAAP same-store NOI - Average rent per square foot can vary significantly by market, but management remains optimistic about strong rental rate growth [76][79] Question: Bad debt levels and tenant watchlist - Bad debt remains a non-factor, with consistent levels around 30 to 35 basis points relative to total revenue [68] Question: Interest rates and leverage levels - Management is monitoring interest rates and plans to utilize debt as opportunities arise, maintaining a strong capital position [70] Question: Regional market strengths and weaknesses - The eastern region, particularly Florida and Raleigh, has shown strength, while California markets, especially LA, have been slower [48][50]

Financial Data and Key Metrics Changes - In Q4 2024, the company achieved $238 million in revenue, representing a 3% organic growth year over year and a 13% reported revenue increase [11] - For the full year 2024, total revenue was $949 million, with an 8% reported revenue growth and a 2% organic decline [13] - Adjusted EBITDA for Q4 2024 was $52 million, a 15% increase from the previous year, while for the full year, it grew 7% to $210 million [42][13] - Operating cash flow reached a record $62 million in Q4 2024, up 58% year over year, and $159 million for the full year, up 32% [45][13] - Non-GAAP adjusted earnings per share for Q4 2024 was $0.76, a 21% increase year over year, and $3.08 for the full year [45] Business Line Data and Key Metrics Changes - The medical market accounted for 55% of total sales in 2024, growing at a high single-digit rate, particularly in minimally invasive surgery and robotics [19] - Advanced industrial markets made up 45% of total sales, growing at a low double-digit rate despite challenges [20] - The automation enabling technologies segment saw a 9% year-over-year sales growth in Q4, while the medical solutions segment experienced a 17% reported revenue growth but a 4% organic decline [50][52] Market Data and Key Metrics Changes - Bookings grew 54% year over year in Q4 2024, driven by major OEM customers confirming new product launches for 2025 [12] - The book-to-bill ratio for the automation enabling technologies segment was 0.89% in Q4, while the medical solutions segment had a book-to-bill of 1.05% [47][54] - The company noted a gradual return of growth in end markets, particularly in robotics and automation applications [16] Company Strategy and Development Direction - The company plans to launch 50% more new products in 2025 compared to 2024, aiming for $50 million in incremental new product revenue [15][38] - The focus remains on leveraging the Novanta growth system to drive operational excellence and margin expansion [36][63] - The company is prioritizing acquisitions aligned with its cash flow compounding strategy, with a robust pipeline of potential targets [27][125] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025 despite market uncertainties, particularly in healthcare markets driven by strong patient procedure growth [14] - The geopolitical disruptions and market economic uncertainty are expected to impact capital spending in various sectors, but the company remains confident in its fundamentals [16][60] - Management highlighted the importance of adapting to changing market conditions and maintaining operational resilience [17] Other Important Information - The company has made significant organizational changes to better scale operations, appointing two co-COOs to lead different segments [29] - The Novanta Way culture is emphasized as a key differentiator in attracting and retaining talent [33] - The company aims to maintain a net leverage ratio below 1.4 times to ensure financial flexibility for acquisitions [46][126] Q&A Session Summary Question: Comments on DNA sequencing product lines and expected recovery - Management noted that shipments have normalized, but funding cuts from the National Institute of Health have created caution among customers, leading to increased volatility in the DNA sequencing market [84][85] Question: Outlook for organic growth in 2026 - Management expects accelerating organic growth in 2026, driven by innovation and new product launches, with a focus on consumables in the advanced surgery business [88][92] Question: Clarification on EUV and DUV subsystem product orders - Management confirmed initial orders for an intelligent subsystem product, with revenue expected to ramp in the second half of the year [98][100] Question: Update on humanoid robotics orders - Management indicated that while the humanoid category is small, it is growing rapidly, with increasing demand for high-precision robotics [102][104] Question: Guidance on the cadence of the $50 million incremental revenue - Management expects a gradual increase in revenue contribution throughout the year, with significant growth anticipated in the second half [111][114] Question: Update on short-cycle business and semiconductor demand - Management reported sustained growth in short-cycle businesses, with positive signs of demand filling in for the first half of 2025 [116] Question: Comfort level around leverage for acquisitions - Management reiterated a disciplined approach to acquisitions, aiming to stay below three times leverage while pursuing meaningful opportunities [125][126]